Elritercept for myelodysplastic syndromes

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 20 Feb 2026: Trial registered, NCT07422480
  2. 21 May 2026: Trial started, NCT07422480

The trials

NCT07422480: A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Lower Risk Myelodysplastic Syndromes (LR-MDS) Who Need Regular Blood Transfusions

State
Under way
Phase
Phase 3
People
300 planned
Started
21 May 2026
Primary completion
30 Apr 2029
Arms
Elritercept
Results
None posted
  1. 20 Feb 2026: Trial registered
  2. 21 May 2026: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.